AS Partners Co. Ltd.

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 6197.T has a market cap of 101.6B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 6197.T trades at ¥1,116.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 6197.T's P/E ratio is 23.47. In terms of profitability, 160A.T's ROE is +0.25%, compared to 6197.T's ROE of +0.18%. Regarding short-term risk, 160A.T is more volatile compared to 6197.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 6197.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 6099.T has a market cap of 44.6B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 6099.T trades at ¥738.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 6099.T's P/E ratio is 16.12. In terms of profitability, 160A.T's ROE is +0.25%, compared to 6099.T's ROE of +0.21%. Regarding short-term risk, 160A.T is more volatile compared to 6099.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 6099.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 6062.T has a market cap of 44.1B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 6062.T trades at ¥1,349.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 6062.T's P/E ratio is 13.33. In terms of profitability, 160A.T's ROE is +0.25%, compared to 6062.T's ROE of +0.16%. Regarding short-term risk, 160A.T is more volatile compared to 6062.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 6062.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7071.T has a market cap of 41.5B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7071.T trades at ¥426.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7071.T's P/E ratio is 11.35. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7071.T's ROE of +0.09%. Regarding short-term risk, 160A.T is more volatile compared to 7071.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 7071.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 2372.T has a market cap of 33.8B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 2372.T trades at ¥2,790.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 2372.T's P/E ratio is 131.60. In terms of profitability, 160A.T's ROE is +0.25%, compared to 2372.T's ROE of +0.11%. Regarding short-term risk, 160A.T is more volatile compared to 2372.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 2372.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 2374.T has a market cap of 29.9B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 2374.T trades at ¥1,212.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 2374.T's P/E ratio is 0.00. In terms of profitability, 160A.T's ROE is +0.25%, compared to 2374.T's ROE of +0.10%. Regarding short-term risk, 160A.T is more volatile compared to 2374.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 2374.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 9158.T has a market cap of 28.8B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 9158.T trades at ¥984.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 9158.T's P/E ratio is 16.62. In terms of profitability, 160A.T's ROE is +0.25%, compared to 9158.T's ROE of +0.06%. Regarding short-term risk, 160A.T is less volatile compared to 9158.T. This indicates potentially lower risk in terms of short-term price fluctuations for 160A.T.Check 9158.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 194A.T has a market cap of 12.1B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 194A.T trades at ¥1,600.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 194A.T's P/E ratio is 16.99. In terms of profitability, 160A.T's ROE is +0.25%, compared to 194A.T's ROE of +0.26%. Regarding short-term risk, 160A.T is less volatile compared to 194A.T. This indicates potentially lower risk in terms of short-term price fluctuations for 160A.T.Check 194A.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 9229.T has a market cap of 8.1B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 9229.T trades at ¥249.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 9229.T's P/E ratio is -2.98. In terms of profitability, 160A.T's ROE is +0.25%, compared to 9229.T's ROE of -0.38%. Regarding short-term risk, 160A.T is less volatile compared to 9229.T. This indicates potentially lower risk in terms of short-term price fluctuations for 160A.T.Check 9229.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7133.T has a market cap of 8B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7133.T trades at ¥1,126.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7133.T's P/E ratio is 14.66. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7133.T's ROE of +0.24%. Regarding short-term risk, 160A.T and 7133.T have similar daily volatility (2.34).Check 7133.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 6557.T has a market cap of 7.7B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 6557.T trades at ¥1,195.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 6557.T's P/E ratio is 16.41. In terms of profitability, 160A.T's ROE is +0.25%, compared to 6557.T's ROE of +0.19%. Regarding short-term risk, 160A.T is more volatile compared to 6557.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 6557.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 8769.T has a market cap of 7.3B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 8769.T trades at ¥463.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 8769.T's P/E ratio is 7.05. In terms of profitability, 160A.T's ROE is +0.25%, compared to 8769.T's ROE of +0.25%. Regarding short-term risk, 160A.T is less volatile compared to 8769.T. This indicates potentially lower risk in terms of short-term price fluctuations for 160A.T.Check 8769.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 6059.T has a market cap of 6.9B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 6059.T trades at ¥353.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 6059.T's P/E ratio is 3.20. In terms of profitability, 160A.T's ROE is +0.25%, compared to 6059.T's ROE of +0.15%. Regarding short-term risk, 160A.T is more volatile compared to 6059.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 6059.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7061.T has a market cap of 6.5B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7061.T trades at ¥776.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7061.T's P/E ratio is 23.61. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7061.T's ROE of +0.08%. Regarding short-term risk, 160A.T is less volatile compared to 7061.T. This indicates potentially lower risk in terms of short-term price fluctuations for 160A.T.Check 7061.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 2373.T has a market cap of 5.9B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 2373.T trades at ¥437.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 2373.T's P/E ratio is 15.35. In terms of profitability, 160A.T's ROE is +0.25%, compared to 2373.T's ROE of +0.12%. Regarding short-term risk, 160A.T is more volatile compared to 2373.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 2373.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7091.T has a market cap of 5.8B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7091.T trades at ¥1,287.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7091.T's P/E ratio is 13.05. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7091.T's ROE of +0.22%. Regarding short-term risk, 160A.T is more volatile compared to 7091.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 7091.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 4172.T has a market cap of 5.2B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 4172.T trades at ¥2,315.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 4172.T's P/E ratio is 11.51. In terms of profitability, 160A.T's ROE is +0.25%, compared to 4172.T's ROE of +0.11%. Regarding short-term risk, 160A.T is more volatile compared to 4172.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 4172.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7037.T has a market cap of 4.1B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7037.T trades at ¥893.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7037.T's P/E ratio is 37.10. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7037.T's ROE of +0.06%. Regarding short-term risk, 160A.T is more volatile compared to 7037.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 7037.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7129.T has a market cap of 3.2B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7129.T trades at ¥1,141.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7129.T's P/E ratio is 9.52. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7129.T's ROE of +0.01%. Regarding short-term risk, 160A.T is more volatile compared to 7129.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 7129.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 9220.T has a market cap of 2.9B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 9220.T trades at ¥1,189.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 9220.T's P/E ratio is 6.64. In terms of profitability, 160A.T's ROE is +0.25%, compared to 9220.T's ROE of +0.13%. Regarding short-term risk, 160A.T is more volatile compared to 9220.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 9220.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 2425.T has a market cap of 2.8B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 2425.T trades at ¥751.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 2425.T's P/E ratio is 10.86. In terms of profitability, 160A.T's ROE is +0.25%, compared to 2425.T's ROE of +0.08%. Regarding short-term risk, 160A.T is more volatile compared to 2425.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 2425.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 2435.T has a market cap of 2.5B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 2435.T trades at ¥220.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 2435.T's P/E ratio is 5.76. In terms of profitability, 160A.T's ROE is +0.25%, compared to 2435.T's ROE of +0.26%. Regarding short-term risk, 160A.T is more volatile compared to 2435.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 2435.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 189A.T has a market cap of 2.1B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 189A.T trades at ¥930.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 189A.T's P/E ratio is 9.81. In terms of profitability, 160A.T's ROE is +0.25%, compared to 189A.T's ROE of +0.10%. Regarding short-term risk, 160A.T is more volatile compared to 189A.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 189A.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 9214.T has a market cap of 1.9B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 9214.T trades at ¥1,406.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 9214.T's P/E ratio is 15.16. In terms of profitability, 160A.T's ROE is +0.25%, compared to 9214.T's ROE of +0.17%. Regarding short-term risk, 160A.T is more volatile compared to 9214.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 9214.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 6029.T has a market cap of 1.5B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 6029.T trades at ¥143.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 6029.T's P/E ratio is 5.68. In terms of profitability, 160A.T's ROE is +0.25%, compared to 6029.T's ROE of +0.16%. Regarding short-term risk, 160A.T is more volatile compared to 6029.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 6029.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7362.T has a market cap of 1.2B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7362.T trades at ¥803.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7362.T's P/E ratio is 14.87. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7362.T's ROE of +0.06%. Regarding short-term risk, 160A.T is less volatile compared to 7362.T. This indicates potentially lower risk in terms of short-term price fluctuations for 160A.T.Check 7362.T's competition here

160A.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 160A.T stands at 7.6B. In comparison, 7363.T has a market cap of 1.1B. Regarding current trading prices, 160A.T is priced at ¥2,120.00, while 7363.T trades at ¥1,285.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

160A.T currently has a P/E ratio of 6.72, whereas 7363.T's P/E ratio is 23.05. In terms of profitability, 160A.T's ROE is +0.25%, compared to 7363.T's ROE of +0.10%. Regarding short-term risk, 160A.T is more volatile compared to 7363.T. This indicates potentially higher risk in terms of short-term price fluctuations for 160A.T.Check 7363.T's competition here